Alexium International Group（AJX）株式概要アレクシウム・インターナショナル・グループ・リミテッドは、米国で難燃性と熱管理を中心とした先端材料用途のパフォーマンスケミカルを提供している。 詳細AJX ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析マイナスの株主資本 Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間9.2%減少しました。 +2 さらなるリスクすべてのリスクチェックを見るAJX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.006531.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m16m2016201920222025202620282031Revenue US$1.7mEarnings US$159.1kAdvancedSet Fair ValueView all narrativesAlexium International Group Limited 競合他社Terragen HoldingsSymbol: ASX:TGHMarket cap: AU$14.0mCarbonxt GroupSymbol: ASX:CG1Market cap: AU$25.6mSciDevSymbol: ASX:SDVMarket cap: AU$25.7mBuxton ResourcesSymbol: ASX:BUXMarket cap: AU$20.1m価格と性能株価の高値、安値、推移の概要Alexium International Group過去の株価現在の株価AU$0.00652週高値AU$0.00852週安値AU$0.005ベータ0.611ヶ月の変化0%3ヶ月変化-14.29%1年変化-14.29%3年間の変化-53.85%5年間の変化-87.23%IPOからの変化-97.00%最新ニュースNew Risk • Mar 05New major risk - Revenue and earnings growthEarnings have declined by 6.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.5m).New Risk • Feb 27New major risk - Revenue and earnings growthEarnings have declined by 9.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.6m).New Risk • Jan 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$19.4m market cap, or US$13.3m).New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Market cap is less than US$10m (AU$11.5m market cap, or US$7.67m). Minor Risk Revenue is less than US$5m (US$3.9m revenue).Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.最新情報をもっと見るRecent updatesNew Risk • Mar 05New major risk - Revenue and earnings growthEarnings have declined by 6.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.5m).New Risk • Feb 27New major risk - Revenue and earnings growthEarnings have declined by 9.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.6m).New Risk • Jan 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$19.4m market cap, or US$13.3m).New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Market cap is less than US$10m (AU$11.5m market cap, or US$7.67m). Minor Risk Revenue is less than US$5m (US$3.9m revenue).Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.お知らせ • Dec 15Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,127,664,547 Price\Range: AUD 0.006 Transaction Features: Rights Offeringお知らせ • Oct 22Alexium International Group Limited, Annual General Meeting, Nov 21, 2025Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 AustraliaBoard Change • Aug 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Aug 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$402k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.8m free cash flow). Negative equity (-US$402k). Market cap is less than US$10m (AU$9.52m market cap, or US$6.22m). Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Revenue is less than US$5m (US$3.9m revenue).お知らせ • Aug 04Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4.Reported Earnings • Feb 27First half 2025 earnings released: US$0.001 loss per share (vs US$0.003 loss in 1H 2024)First half 2025 results: US$0.001 loss per share (improved from US$0.003 loss in 1H 2024). Revenue: US$2.29m (down 17% from 1H 2024). Net loss: US$1.66m (loss narrowed 16% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.New Risk • Feb 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.8m (US$9.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (138% increase in shares outstanding). Market cap is less than US$10m (AU$15.8m market cap, or US$9.75m).Board Change • Nov 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive & Independent Director Randall Lane was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 18Alexium International Group Limited, Annual General Meeting, Nov 20, 2024Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. AustraliaReported Earnings • Aug 30Full year 2024 earnings releasedFull year 2024 results: Revenue: US$5.89m (down 18% from FY 2023). Net loss: US$2.76m (loss narrowed 6.4% from FY 2023).New Risk • Aug 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.5m (US$8.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Market cap is less than US$10m (AU$12.5m market cap, or US$8.36m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Carl Dennis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Jun 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.7m market cap, or US$12.3m).New Risk • May 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 139% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (AU$18.7m market cap, or US$12.4m).New Risk • May 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.1m). Market cap is less than US$10m (AU$10.5m market cap, or US$6.93m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (47% increase in shares outstanding).Reported Earnings • Feb 29First half 2024 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1H 2023)First half 2024 results: US$0.003 loss per share (improved from US$0.004 loss in 1H 2023). Revenue: US$2.77m (down 20% from 1H 2023). Net loss: US$1.96m (loss narrowed 17% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings.お知らせ • Dec 27+ 1 more updateAlexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 38,461,538 Price\Range: AUD 0.013 Transaction Features: Subsequent Direct ListingNew Risk • Dec 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (AU$9.92m market cap, or US$6.71m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).お知らせ • Oct 26Alexium International Group Limited Announces Resignation of Stephen Cheney as Non-Executive Director, Effective 1 November 2023Alexium International Group Limited announced that Brigadier General Stephen Cheney, USMC (Ret) has advised the Company of his intention to resign as Non-Executive Director of Alexium, effective 1 November 2023. Mr. Cheney has been a Non-Executive Director of Alexium since April 2015 and has served on the Company's Audit, Nomination & Remuneration, and Risk Committees.New Risk • Oct 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (AU$11.2m market cap, or US$7.13m). Minor Risk Shareholders have been diluted in the past year (2.0% increase in shares outstanding).お知らせ • Sep 27Alexium International Group Limited, Annual General Meeting, Nov 15, 2023Alexium International Group Limited, Annual General Meeting, Nov 15, 2023, at 10:30 AUS Eastern Standard Time. Location: offices of Grant Thornton, Level 17, 383 Kent Street, 2000 Sydney New South Wales Australia Agenda: To consider the election of director.Reported Earnings • Aug 25Full year 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in FY 2022)Full year 2023 results: US$0.005 loss per share (in line with FY 2022). Revenue: US$7.21m (down 12% from FY 2022). Net loss: US$2.95m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 25First half 2023 earnings releasedFirst half 2023 results: Revenue: US$3.44m (down 35% from 1H 2022). Net loss: US$2.37m (loss widened 22% from 1H 2022).分析記事 • Dec 23Alexium International Group (ASX:AJX) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 13Alexium International Group Limited, Annual General Meeting, Nov 16, 2022Alexium International Group Limited, Annual General Meeting, Nov 16, 2022, at 10:30 AUS Eastern Standard Time.お知らせ • Sep 02Alexium International Group Limited Appoints William Timothy Blackburn as DirectorAlexium International Group Limited appointed William Timothy Blackburn as Director. Date of appointment is 1 September 2022.分析記事 • Aug 30Here's Why Alexium International Group (ASX:AJX) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Aug 26Full year 2022 earnings released: US$0.005 loss per share (vs US$0.002 loss in FY 2021)Full year 2022 results: US$0.005 loss per share (down from US$0.002 loss in FY 2021). Revenue: US$8.17m (up 12% from FY 2021). Net loss: US$3.36m (loss widened 133% from FY 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Aug 02+ 1 more updateAlexium International Group Limited Announces Executive ChangesAlexium International Group Limited announced that Billy Blackburn has been appointed CEO and Managing Director of Alexium, effective 1 September 2022. In this transition, Dr. Bob Brookins has been appointed Chief Technology Officer (CTO) and will remain an executive director on the Board. Mr. Blackburn has an accomplished background having founded a high-growth technology company specialising in high purity solvents, which was subsequently sold to Nova Molecular. Mr. Blackburn was appointed Vice President, Business Development at Nova Molecular where he was responsible for substantial revenue growth that included securing major consumer healthcare contracts. More recently, Mr. Blackburn has been the Vice President & Executive Manager with Giant Cement Holdings Inc., which is focused on Renewable Waste Processes.Reported Earnings • Mar 01First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: US$0.003 loss per share (vs US$0.003 loss in 1H 2021). Revenue: US$5.28m (up 46% from 1H 2021). Net loss: US$1.95m (loss widened 8.9% from 1H 2021). Revenue exceeded analyst estimates by 176%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.分析記事 • Oct 08Is Alexium International Group (ASX:AJX) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Aug 29Full year 2021 earnings released: US$0.002 loss per share (vs US$0.013 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$7.28m (up 20% from FY 2020). Net loss: US$1.45m (loss narrowed 76% from FY 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • May 21Alexium International Group Limited Announces the First Sales and Commercial Launch of A Suite of AlexicoolAlexium International Group Limited announced the first sales and commercial launch of a suite of Alexicool® products for a total mattress cooling system (TMCS). This satisfies a key milestone in the Company's strategic initiative for growth in the US bedding market and serves to grow and diversify the Company's revenue streams. Importantly, this initiative both extends and deepens lexium's customer base, provides increased visibility to revenues and further differentiates Alexium from the competition. The Company anticipates further significant growth in this market as it incorporates other proprietary technologies into TMCS designs.分析記事 • May 03Alexium International Group (ASX:AJX) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Feb 26First half 2021 earnings released: US$0.003 loss per share (vs US$0.012 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: US$3.61m (up 14% from 1H 2020). Net loss: US$1.79m (loss narrowed 59% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.分析記事 • Jan 18Should You Take Comfort From Insider Transactions At Alexium International Group Limited (ASX:AJX)?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...お知らせ • Dec 04Alexium International Group Limited Announces Commercialization of a New Line of Proprietary Biobased and Biodegradable Phase Change Materials for Thermal Management ApplicationsAlexium International Group Limited announced the commercialization of a new line of proprietary biobased and biodegradable phase change materials for thermal management applications. Beyond the environmental benefits, these products provide further performance enhancements and expand the range of applicable market segments for the Alexicool® portfolio. Phase change materials (PCMs) are the key active material for the Company's Alexicool® products and are used in a range of consumer products including bedding materials and activewear. The new biobased PCM products were developed with corporate partners and leverage a range of insights gained from Alexium's years of research and analytics in thermal management applications. These benefits include: Certified biobased & biodegradable PCMs; Improved rate of activation to its active form; Improved handling during manufacturing; Cost competitive. Additionally, this platform allows for the Company to expand its portfolio to address a broader range of end products and to better meet customer needs.お知らせ • Dec 01Alexium International Group Limited Announces Resignation of Belinda Cleminson, Joint Company Secretary Effective December 1, 2020The Board of Alexium International Group Limited announced that, following her resignation from Mertons Corporate Services Pty Ltd, Belinda Cleminson has also resigned as Joint Company Secretary of Alexium International effective December 1, 2020. Mertons Managing Director Mark Licciardo continues to serve as Company Secretary.分析記事 • Nov 27What We Learned About Alexium International Group's (ASX:AJX) CEO CompensationBob Brookins became the CEO of Alexium International Group Limited (ASX:AJX) in 2018, and we think it's a good time to...お知らせ • Nov 03Allen Reihman, Chief Commercial Officer Leaves Alexium International Group LimitedAlexium International Group Limited announced that Chief Commercial Officer Allen Reihman will leave the organization with effect from 3 November 2020. The Company's intention is to eliminate this position with the role of commercial lead subsequently being held by the incoming Vice-President, Sales and Marketing.お知らせ • Sep 04Alexium International Group Limited Auditor Raises 'Going Concern' DoubtAlexium International Group Limited filed its Annual on Aug 27, 2020 for the period ending Jun 30, 2020. In this report its auditor, Grant Thornton, gave a qualified opinion expressing doubt that the company can continue as a going concern.分析記事 • Jun 17How Many Alexium International Group Limited (ASX:AJX) Shares Did Insiders Buy, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...株主還元AJXAU ChemicalsAU 市場7D-14.3%2.1%0.03%1Y-14.3%22.0%2.3%株主還元を見る業界別リターン: AJX過去 1 年間で22 % の収益を上げたAustralian Chemicals業界を下回りました。リターン対市場: AJXは、過去 1 年間で2.3 % のリターンを上げたAustralian市場を下回りました。価格変動Is AJX's price volatile compared to industry and market?AJX volatilityAJX Average Weekly Movement28.5%Chemicals Industry Average Movement10.2%Market Average Movement9.8%10% most volatile stocks in AU Market17.1%10% least volatile stocks in AU Market4.0%安定した株価: AJXの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: AJXの 週次ボラティリティ は、過去 1 年間で22%から28%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aBilly Blackburnwww.alexiuminternational.comアレクシウム・インターナショナル・グループ・リミテッドは、米国で難燃性と熱管理に重点を置いた先端材料用途のパフォーマンスケミカルを提供している。布地用PCM仕上げ処理剤Alexicool、天然・バイオベースのマイクロカプセル化PCM冷却剤Biocool、冷却効果を高める永久冷却技術Eclipsys、熱管理製品DelCoolなどの熱調整ソリューションを提供している。また、綿とセルロースベースのテキスタイル用難燃加工「アレキシフラム」、ポリエステル100％生地用の難燃エマルジョン「アレキシガード」、マットレスの難燃性を高める耐水性難燃ソリューション「アレキシシールド」などの難燃ソリューションも提供している。寝具、ボディーアーマー、軍服、作業着市場に製品を供給している。本社はサウスカロライナ州グリア。もっと見るAlexium International Group Limited 基礎のまとめAlexium International Group の収益と売上を時価総額と比較するとどうか。AJX 基礎統計学時価総額AU$18.77m収益（TTM）-AU$6.33m売上高(TTM)AU$4.96m3.8xP/Sレシオ-3.0xPER（株価収益率AJX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AJX 損益計算書（TTM）収益US$3.42m売上原価US$1.97m売上総利益US$1.46mその他の費用US$5.82m収益-US$4.37m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0014グロス・マージン42.54%純利益率-127.51%有利子負債／自己資本比率-153.1%AJX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 21:14終値2026/07/01 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alexium International Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 05New major risk - Revenue and earnings growthEarnings have declined by 6.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.5m).
New Risk • Feb 27New major risk - Revenue and earnings growthEarnings have declined by 9.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.6m).
New Risk • Jan 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$19.4m market cap, or US$13.3m).
New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Market cap is less than US$10m (AU$11.5m market cap, or US$7.67m). Minor Risk Revenue is less than US$5m (US$3.9m revenue).
Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.
New Risk • Mar 05New major risk - Revenue and earnings growthEarnings have declined by 6.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.5m).
New Risk • Feb 27New major risk - Revenue and earnings growthEarnings have declined by 9.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$402k). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (AU$21.9m market cap, or US$15.6m).
New Risk • Jan 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (AU$19.4m market cap, or US$13.3m).
New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$402k). Market cap is less than US$10m (AU$11.5m market cap, or US$7.67m). Minor Risk Revenue is less than US$5m (US$3.9m revenue).
Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 16Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group.Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc. Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025.
お知らせ • Dec 15Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,127,664,547 Price\Range: AUD 0.006 Transaction Features: Rights Offering
お知らせ • Oct 22Alexium International Group Limited, Annual General Meeting, Nov 21, 2025Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 Australia
Board Change • Aug 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Aug 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$402k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.8m free cash flow). Negative equity (-US$402k). Market cap is less than US$10m (AU$9.52m market cap, or US$6.22m). Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Revenue is less than US$5m (US$3.9m revenue).
お知らせ • Aug 04Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4.
Reported Earnings • Feb 27First half 2025 earnings released: US$0.001 loss per share (vs US$0.003 loss in 1H 2024)First half 2025 results: US$0.001 loss per share (improved from US$0.003 loss in 1H 2024). Revenue: US$2.29m (down 17% from 1H 2024). Net loss: US$1.66m (loss narrowed 16% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
New Risk • Feb 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.8m (US$9.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (138% increase in shares outstanding). Market cap is less than US$10m (AU$15.8m market cap, or US$9.75m).
Board Change • Nov 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive & Independent Director Randall Lane was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 18Alexium International Group Limited, Annual General Meeting, Nov 20, 2024Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. Australia
Reported Earnings • Aug 30Full year 2024 earnings releasedFull year 2024 results: Revenue: US$5.89m (down 18% from FY 2023). Net loss: US$2.76m (loss narrowed 6.4% from FY 2023).
New Risk • Aug 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.5m (US$8.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Market cap is less than US$10m (AU$12.5m market cap, or US$8.36m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Carl Dennis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Jun 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.7m market cap, or US$12.3m).
New Risk • May 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 139% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (AU$18.7m market cap, or US$12.4m).
New Risk • May 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.1m). Market cap is less than US$10m (AU$10.5m market cap, or US$6.93m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (47% increase in shares outstanding).
Reported Earnings • Feb 29First half 2024 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1H 2023)First half 2024 results: US$0.003 loss per share (improved from US$0.004 loss in 1H 2023). Revenue: US$2.77m (down 20% from 1H 2023). Net loss: US$1.96m (loss narrowed 17% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings.
お知らせ • Dec 27+ 1 more updateAlexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 38,461,538 Price\Range: AUD 0.013 Transaction Features: Subsequent Direct Listing
New Risk • Dec 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (AU$9.92m market cap, or US$6.71m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
お知らせ • Oct 26Alexium International Group Limited Announces Resignation of Stephen Cheney as Non-Executive Director, Effective 1 November 2023Alexium International Group Limited announced that Brigadier General Stephen Cheney, USMC (Ret) has advised the Company of his intention to resign as Non-Executive Director of Alexium, effective 1 November 2023. Mr. Cheney has been a Non-Executive Director of Alexium since April 2015 and has served on the Company's Audit, Nomination & Remuneration, and Risk Committees.
New Risk • Oct 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (AU$11.2m market cap, or US$7.13m). Minor Risk Shareholders have been diluted in the past year (2.0% increase in shares outstanding).
お知らせ • Sep 27Alexium International Group Limited, Annual General Meeting, Nov 15, 2023Alexium International Group Limited, Annual General Meeting, Nov 15, 2023, at 10:30 AUS Eastern Standard Time. Location: offices of Grant Thornton, Level 17, 383 Kent Street, 2000 Sydney New South Wales Australia Agenda: To consider the election of director.
Reported Earnings • Aug 25Full year 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in FY 2022)Full year 2023 results: US$0.005 loss per share (in line with FY 2022). Revenue: US$7.21m (down 12% from FY 2022). Net loss: US$2.95m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 25First half 2023 earnings releasedFirst half 2023 results: Revenue: US$3.44m (down 35% from 1H 2022). Net loss: US$2.37m (loss widened 22% from 1H 2022).
分析記事 • Dec 23Alexium International Group (ASX:AJX) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 13Alexium International Group Limited, Annual General Meeting, Nov 16, 2022Alexium International Group Limited, Annual General Meeting, Nov 16, 2022, at 10:30 AUS Eastern Standard Time.
お知らせ • Sep 02Alexium International Group Limited Appoints William Timothy Blackburn as DirectorAlexium International Group Limited appointed William Timothy Blackburn as Director. Date of appointment is 1 September 2022.
分析記事 • Aug 30Here's Why Alexium International Group (ASX:AJX) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Aug 26Full year 2022 earnings released: US$0.005 loss per share (vs US$0.002 loss in FY 2021)Full year 2022 results: US$0.005 loss per share (down from US$0.002 loss in FY 2021). Revenue: US$8.17m (up 12% from FY 2021). Net loss: US$3.36m (loss widened 133% from FY 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Aug 02+ 1 more updateAlexium International Group Limited Announces Executive ChangesAlexium International Group Limited announced that Billy Blackburn has been appointed CEO and Managing Director of Alexium, effective 1 September 2022. In this transition, Dr. Bob Brookins has been appointed Chief Technology Officer (CTO) and will remain an executive director on the Board. Mr. Blackburn has an accomplished background having founded a high-growth technology company specialising in high purity solvents, which was subsequently sold to Nova Molecular. Mr. Blackburn was appointed Vice President, Business Development at Nova Molecular where he was responsible for substantial revenue growth that included securing major consumer healthcare contracts. More recently, Mr. Blackburn has been the Vice President & Executive Manager with Giant Cement Holdings Inc., which is focused on Renewable Waste Processes.
Reported Earnings • Mar 01First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: US$0.003 loss per share (vs US$0.003 loss in 1H 2021). Revenue: US$5.28m (up 46% from 1H 2021). Net loss: US$1.95m (loss widened 8.9% from 1H 2021). Revenue exceeded analyst estimates by 176%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
分析記事 • Oct 08Is Alexium International Group (ASX:AJX) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Aug 29Full year 2021 earnings released: US$0.002 loss per share (vs US$0.013 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$7.28m (up 20% from FY 2020). Net loss: US$1.45m (loss narrowed 76% from FY 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • May 21Alexium International Group Limited Announces the First Sales and Commercial Launch of A Suite of AlexicoolAlexium International Group Limited announced the first sales and commercial launch of a suite of Alexicool® products for a total mattress cooling system (TMCS). This satisfies a key milestone in the Company's strategic initiative for growth in the US bedding market and serves to grow and diversify the Company's revenue streams. Importantly, this initiative both extends and deepens lexium's customer base, provides increased visibility to revenues and further differentiates Alexium from the competition. The Company anticipates further significant growth in this market as it incorporates other proprietary technologies into TMCS designs.
分析記事 • May 03Alexium International Group (ASX:AJX) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Feb 26First half 2021 earnings released: US$0.003 loss per share (vs US$0.012 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: US$3.61m (up 14% from 1H 2020). Net loss: US$1.79m (loss narrowed 59% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
分析記事 • Jan 18Should You Take Comfort From Insider Transactions At Alexium International Group Limited (ASX:AJX)?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
お知らせ • Dec 04Alexium International Group Limited Announces Commercialization of a New Line of Proprietary Biobased and Biodegradable Phase Change Materials for Thermal Management ApplicationsAlexium International Group Limited announced the commercialization of a new line of proprietary biobased and biodegradable phase change materials for thermal management applications. Beyond the environmental benefits, these products provide further performance enhancements and expand the range of applicable market segments for the Alexicool® portfolio. Phase change materials (PCMs) are the key active material for the Company's Alexicool® products and are used in a range of consumer products including bedding materials and activewear. The new biobased PCM products were developed with corporate partners and leverage a range of insights gained from Alexium's years of research and analytics in thermal management applications. These benefits include: Certified biobased & biodegradable PCMs; Improved rate of activation to its active form; Improved handling during manufacturing; Cost competitive. Additionally, this platform allows for the Company to expand its portfolio to address a broader range of end products and to better meet customer needs.
お知らせ • Dec 01Alexium International Group Limited Announces Resignation of Belinda Cleminson, Joint Company Secretary Effective December 1, 2020The Board of Alexium International Group Limited announced that, following her resignation from Mertons Corporate Services Pty Ltd, Belinda Cleminson has also resigned as Joint Company Secretary of Alexium International effective December 1, 2020. Mertons Managing Director Mark Licciardo continues to serve as Company Secretary.
分析記事 • Nov 27What We Learned About Alexium International Group's (ASX:AJX) CEO CompensationBob Brookins became the CEO of Alexium International Group Limited (ASX:AJX) in 2018, and we think it's a good time to...
お知らせ • Nov 03Allen Reihman, Chief Commercial Officer Leaves Alexium International Group LimitedAlexium International Group Limited announced that Chief Commercial Officer Allen Reihman will leave the organization with effect from 3 November 2020. The Company's intention is to eliminate this position with the role of commercial lead subsequently being held by the incoming Vice-President, Sales and Marketing.
お知らせ • Sep 04Alexium International Group Limited Auditor Raises 'Going Concern' DoubtAlexium International Group Limited filed its Annual on Aug 27, 2020 for the period ending Jun 30, 2020. In this report its auditor, Grant Thornton, gave a qualified opinion expressing doubt that the company can continue as a going concern.
分析記事 • Jun 17How Many Alexium International Group Limited (ASX:AJX) Shares Did Insiders Buy, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
